Mirvaso (Brimonidine Tartrate)

Brimonidine tartrate, the active ingredient in Mirvaso, is an alpha‑2 adrenergic agonist presented as a topical gel for topical use. It selectively constricts cutaneous blood vessels, helping to reduce facial erythema in adults with rosacea. It is indicated for the treatment of persistent facial redness and is approved for use in the European Union.

GNH USA supplies Mirvaso as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for this prescription‑only product.

Mirvaso (brimonidine tartrate) is a topical vasoconstrictor used in the management of rosacea‑related facial erythema.

- Facial erythema of rosacea: reduces persistent redness. - Rosacea‑related flushing: diminishes visible blood‑vessel dilation. - Post‑inflammatory erythema in rosacea: improves skin tone.

Common Side Effects: - Skin irritation: mild redness or discomfort at the application site. - Burning or stinging sensation. - Dryness of the treated area. - Pruritus (itching). - Erythema (localized redness). - Flushing.

Serious or Rare Side Effects: - Allergic contact dermatitis. - Severe skin ulceration. - Worsening of rosacea symptoms. - Systemic hypotension from extensive absorption. - Ocular irritation if applied near the eyes. - Anaphylactic reaction (rare).

Mirvaso should be applied only to intact facial skin and avoided on mucous membranes.

- Pregnancy: insufficient data; use only if clearly needed. - Breastfeeding: unknown safety; consider risk vs benefit. - Concomitant use with other topical vasoconstrictors may increase local irritation. - Avoid applying to broken or inflamed skin. - Discontinue if severe irritation or allergic reaction occurs. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Mirvaso may interact with other agents that affect vascular tone or skin integrity.

Major Interactions (Avoid): - Concurrent use of other topical alpha‑2 agonists (e.g., clonidine gel). - Systemic alpha‑2 agonists such as clonidine or guanfacine.

Moderate Interactions (Monitor Closely): - Topical irritants or exfoliants applied to the same area. - Alcohol‑based skin products that may increase irritation. - Other vasoconstrictive agents (e.g., phenylephrine) applied nearby.